---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-26-000096"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2026-08-05T20:09:37+00:00"
generated_at: "2026-08-05T20:12:06.452633+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q2 2026 revenue $628.7M, GAAP EPS $0.82, non-GAAP EPS $0.91

## Summary
- Total revenues $628.7M, up 11% YoY; cabozantinib U.S. net product revenues $573.0M.
- GAAP net income $212.1M ($0.82 diluted EPS) vs $184.8M ($0.65) in Q2 2025.
- Non-GAAP net income $237.1M ($0.91 diluted EPS) vs $212.6M ($0.75) YoY.
- R&D expenses $212.0M, SG&A $147.6M; both up YoY on clinical and marketing costs.
- Zanzalintinib potential launch in metastatic colorectal cancer pending regulatory approval later 2026.

## SEC filing metadata
- accession: 0000939767-26-000096
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2026-08-05T20:09:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/0000939767-26-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-26-000096
- JSON: https://secwatch.observer/filing/0000939767-26-000096.json
- Plain text: https://secwatch.observer/filing/0000939767-26-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.